ES2096262T3 - Nuevas cyclosporins modificadas en la posicion 1. - Google Patents

Nuevas cyclosporins modificadas en la posicion 1.

Info

Publication number
ES2096262T3
ES2096262T3 ES93810113T ES93810113T ES2096262T3 ES 2096262 T3 ES2096262 T3 ES 2096262T3 ES 93810113 T ES93810113 T ES 93810113T ES 93810113 T ES93810113 T ES 93810113T ES 2096262 T3 ES2096262 T3 ES 2096262T3
Authority
ES
Spain
Prior art keywords
new modified
cyclosporins
amino
modified cyclosporins
2alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93810113T
Other languages
English (en)
Inventor
Johann Jakob Boelsterli
Marcel Karl Eberle
Reto Naef
Trevor Glyn Payne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Application granted granted Critical
Publication of ES2096262T3 publication Critical patent/ES2096262T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Gasification And Melting Of Waste (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

CICLOSPORINAS EN DONDE EL RESIDUO DE LA POSICION 1 TIENE LA FORMULA I EN QUE -X-YO S Y R ES HIDROGENO, ALKILO C1-3, ALCOXI, ALKILTIO O AMINO O MONO O DI-(ALKIL C1-2)-AMINO OPCIONALMENTE SUSTITUIDOS POR HALO O HIDROXI, QUE SON UTILES PARA COMPOSICIONES FARMACEUTICAS, PREFERENTEMENTE DE ADMINISTRACION TOPICA Y EN PARTICULAR PARA EL TRATAMIENTO DEL ASMA.
ES93810113T 1992-03-02 1993-02-22 Nuevas cyclosporins modificadas en la posicion 1. Expired - Lifetime ES2096262T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929204466A GB9204466D0 (en) 1992-03-02 1992-03-02 Improvements in or relating to organic compounds

Publications (1)

Publication Number Publication Date
ES2096262T3 true ES2096262T3 (es) 1997-03-01

Family

ID=10711333

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93810113T Expired - Lifetime ES2096262T3 (es) 1992-03-02 1993-02-22 Nuevas cyclosporins modificadas en la posicion 1.

Country Status (26)

Country Link
US (1) US5643870A (es)
EP (1) EP0577544B1 (es)
JP (1) JP3382656B2 (es)
KR (1) KR100256988B1 (es)
CN (1) CN1037104C (es)
AT (1) ATE146484T1 (es)
AU (1) AU667072B2 (es)
CA (1) CA2090634C (es)
CZ (1) CZ285421B6 (es)
DE (1) DE69306670T2 (es)
DK (1) DK0577544T3 (es)
ES (1) ES2096262T3 (es)
FI (1) FI111729B (es)
GB (1) GB9204466D0 (es)
GR (1) GR3022539T3 (es)
HU (1) HU214028B (es)
IL (1) IL104891A (es)
MX (1) MX9301129A (es)
MY (1) MY106921A (es)
NO (1) NO310685B1 (es)
NZ (1) NZ247031A (es)
PL (1) PL174816B1 (es)
RU (1) RU2131883C1 (es)
SK (1) SK279529B6 (es)
TW (1) TW264472B (es)
ZA (1) ZA931491B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639852A (en) * 1994-09-01 1997-06-17 Wisconsin Alumni Research Foundation Immunostimulatory agents
CN1130373C (zh) * 1996-09-13 2003-12-10 诺瓦蒂斯有限公司 [3'－脱氧－3'－氧代－MeBmt]'环孢菌素制备方法
US6517860B1 (en) 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
ATE314388T1 (de) 1997-10-08 2006-01-15 Isotechnika Inc Deuterierte und undeuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agentien
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US6784156B2 (en) * 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
US6809077B2 (en) * 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
US20030087813A1 (en) * 2001-10-12 2003-05-08 Or Yat Sun Cyclosporin analogs for the treatment of lung diseases
SI1436321T1 (sl) 2001-10-19 2006-12-31 Isotechnika Inc Sinteza analogov ciklosporina
US7012065B2 (en) * 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
EP1603512A2 (en) * 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Novel cyclosporins
US20040266669A1 (en) * 2003-06-20 2004-12-30 Wu Frank X. H. Cyclosporin derivatives for the treatment of immune disorders
JP2006014722A (ja) 2004-06-02 2006-01-19 Keio Gijuku 遺伝子マーカー及びその利用
JP2008514701A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
US7511013B2 (en) * 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
JP2008515886A (ja) * 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
EP1814902B1 (en) * 2004-11-22 2008-10-22 Astellas Pharma Inc. Cyclosporine analogue
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
EP2197461B1 (en) 2007-10-08 2018-02-21 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
AU2009276241A1 (en) * 2008-07-30 2010-02-04 Ciclofilin Pharmaceuticals Corp. Nonimmunosuppressive cyclosporine analogue molecules
ES2537385T3 (es) 2009-06-09 2015-06-08 Aurinia Pharmaceuticals Inc. Sistemas de suministro tópico para uso oftálmico
US20130267460A1 (en) * 2010-09-16 2013-10-10 The Johns Hopkins University Methods of Inhibiting Alphavirus Replication and Treating Alphavirus Infection
US9200038B2 (en) 2010-12-15 2015-12-01 Ciclofilin Pharmaceuticals Corp. Cyclosporine analogue molecules modified at amino acid 1 and 3
CN105076117B (zh) * 2014-10-31 2017-08-25 北京林业大学 一种种子抗老化剂及其制备方法
KR20170000243U (ko) 2015-07-09 2017-01-18 (주)하나피앤씨 배관연결용 플랜지 기구
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4764503A (en) * 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
EP0283801A3 (en) * 1987-03-27 1990-05-30 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
ATE95193T1 (de) * 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
CA2004626A1 (en) * 1988-12-05 1990-06-05 Bernard F. Erlanger Derivatives of cyclosporine a, antibodies directed thereto and uses thereof
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
GB8916901D0 (en) * 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
US5202310A (en) * 1990-06-06 1993-04-13 Levy Gary A Cyclosporine metabolites
EP0484281B2 (en) * 1990-11-02 2000-11-22 Novartis AG Cyclosporins

Also Published As

Publication number Publication date
RU2131883C1 (ru) 1999-06-20
SK279529B6 (sk) 1998-12-02
CZ30393A3 (en) 1994-02-16
JPH07252296A (ja) 1995-10-03
CN1076453A (zh) 1993-09-22
MY106921A (en) 1995-08-30
AU3387293A (en) 1993-09-09
CA2090634A1 (en) 1993-09-03
MX9301129A (es) 1994-07-29
PL174816B1 (pl) 1998-09-30
IL104891A (en) 1997-04-15
AU667072B2 (en) 1996-03-07
FI930912A0 (fi) 1993-03-01
IL104891A0 (en) 1993-07-08
HU9300418D0 (en) 1993-05-28
SK14093A3 (en) 1993-10-06
DE69306670D1 (de) 1997-01-30
PL297902A1 (en) 1993-09-06
JP3382656B2 (ja) 2003-03-04
KR930019692A (ko) 1993-10-18
US5643870A (en) 1997-07-01
HUT64567A (en) 1994-01-28
NO310685B1 (no) 2001-08-13
TW264472B (es) 1995-12-01
EP0577544B1 (en) 1996-12-18
HU214028B (en) 1997-12-29
DK0577544T3 (da) 1997-04-01
KR100256988B1 (ko) 2000-05-15
CA2090634C (en) 2005-12-13
ATE146484T1 (de) 1997-01-15
GR3022539T3 (en) 1997-05-31
EP0577544A1 (en) 1994-01-05
FI930912A (fi) 1993-09-03
CZ285421B6 (cs) 1999-08-11
DE69306670T2 (de) 1997-07-03
CN1037104C (zh) 1998-01-21
NZ247031A (en) 1995-05-26
NO930738L (no) 1993-09-03
ZA931491B (en) 1994-09-02
NO930738D0 (no) 1993-03-01
GB9204466D0 (en) 1992-04-15
FI111729B (fi) 2003-09-15

Similar Documents

Publication Publication Date Title
ES2096262T3 (es) Nuevas cyclosporins modificadas en la posicion 1.
ES2144421T3 (es) Nuevo derivado tetrapeptidico.
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
CA2135575A1 (fr) Composition cosmetique contenant en tant qu'agent reducteur un n-mercapto-alkyl alcanediamide ou l'un de ses sels cosmetiquement acceptable
ATE107499T1 (de) Haarkräftigungsmittel.
MX9504332A (es) Derivados de amino(tio)eter y procedimiento para su preparacion.
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
GB9305718D0 (en) Medicaments
DE69324826D1 (de) Gegen Papillomaviren wirksame 2',5'-OLIGOADENYLAT-2',3'-CYCLOPHOSPHATE und 2',5'-OLIGOADENYLATE
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
YU48480B (sh) Novi retinoidi
HK1012847A1 (en) Levobupivacaine and its use as an anaesthetic in pregnant women
ATE308616T1 (de) Rantes mutanten und deren therapeutische verwendungen
ZA945153B (en) 10-Substituted 1 8-dihydroxy-9(10h) anthracenone pharmaceuticals
ZA942686B (en) Active compound from a sponge
IT1266646B1 (it) Dispositivo di chiusura per contenitori,in particolare per contenitori di agenti anestetici
Palani Professor Dr. N. Subbu Reddiar's contributions for the enrichment of Tamil
MY111222A (en) N-[[1-[4-(4-fluorophenoxy)butyl]-4-piperidinyl]-n-methyl-amino]-2-benzothiazolols as class iii antiarrhythmic agents.
IT1256925B (it) Impiego di frammenti o/e di derivati della timosina alfa 1.
IT226014Y1 (it) Dispositivo per l'erogazione di ossigeno terapeutico portatile per l'e mergenza e utilizzabile anche come aerosol con innesto di fiala con es
MY128749A (en) Fungicidal mixtures

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 577544

Country of ref document: ES